New developments in the management of waldenström macroglobulinemia

Jithma P. Abeykoon, Uday Yanamandra, Prashant Kapoor

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Waldenström macroglobulinemia (WM) is a rare, immunoglobulin M-associated lymphoplasmacytic lymphoma. With the recent discoveries of CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) and MYD88 mutations, our understanding of the biology of WM has expanded substantially. While WM still remains incurable, the field is rapidly evolving, and a number of promising agents with significant activity in this malignancy are being evaluated currently. In this review, we discuss the new developments that have occurred in WM over the past 15 years, with a focus on the role of ibrutinib, an oral Bruton’s tyrosine kinase inhibitor that has recently been approved for WM in the United States, Europe, and Canada.

Original languageEnglish (US)
Pages (from-to)73-83
Number of pages11
JournalCancer Management and Research
StatePublished - Mar 10 2017


  • CXCR4
  • Ibrutinib
  • Indolent lymphoma
  • Lymphoplasmacytic lymphoma
  • MYD88
  • Management

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'New developments in the management of waldenström macroglobulinemia'. Together they form a unique fingerprint.

Cite this